Navigation Links
Scripps Pioneers Individualized Medicine by Offering Genetic Testing to Stent Patients
Date:10/7/2009

Individualized Therapies Now Available for Anti-Clogging Medications

San Diego, CA (Vocus) October 9, 2009 -- In what is believed to be a first for a health system in the United States, Scripps Health is now offering genetic testing as part of its care for cardiovascular patients planning to undergo elective stent procedures.

The tests will determine if patients have one or more of the common gene variants linked to an inability to metabolize the anti-clotting drug Plavix (clopidrogel). Plavix is the second-most commonly prescribed drug in the United States and is given to most patients after they receive coronary stents.

The genetic test results will give doctors vastly improved data that will lead to an individualized approach to each patient's treatment following a stent procedure. Stents are tiny metal tubes that cardiologists use to open clogged arteries.

Genetic testing for this population carries significant implications for patient care, as more than 1 million people undergo stent procedures in the U.S. every year. The gene variants associated with an inability to metabolize Plavix occur in more than 30 percent people of European ancestry and more than 40 percent of those of African or Asian ancestry. People with these gene variants carry double or triple the risk of death, heart attack or stroke, compared to people with the normal metabolism alleles in multiple large-scale studies.

"This represents a landmark program in individualized medicine, based on considerable new data and new choices for one of the most commonly prescribed medications and medical procedures in the world," said Dr. Eric Topol, chief academic officer of Scripps Health. "This program demonstrates Scripps Health's commitment to being at the forefront of individualized cardiovascular medicine."

Scripps Health provides more cardiovascular care than any oth
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Scripps Research scientists shed new light on how antibodies fight HIV
2. Scripps Health Treats More Than 160 Fire Victims at Emergency Departments Across San Diego County
3. Scripps research scientists discover chemical triggers for aggression in mice
4. Scripps research scientists find new genetic mutation that halts the development of lupus
5. Scripps scientists find calcium channel blockers help normalize lysosomal storage disease cells
6. Scripps scientists peg wind as the force behind fish booms and busts
7. Scripps research scientists devise approach that stops HIV at earliest stage of infection
8. Scripps Florida awarded $7.6 million grant to develop novel treatment for Parkinsons disease
9. Scripps research team wins $4M grant to study effects of chronic marijuana use
10. Scripps Florida scientists develop a process to disrupt hepatitis C virion production
11. Scripps Memorial Hospital Nurses Throw Out CNA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... McCullers, MD, was recently invited to submit a ... Reviews Microbiology , one of the world,s foremost ... disease specialist, and chair of the Department of ... Center, analyzed the epidemiology and microbiology of co-infections ... well as more recent 2009 novel H1N1 pandemic. ...
(Date:4/17/2014)... Doctors who treat patients with a severe ... face an agonizing treatment decision. , The drug ... help relieve shortness of breath. But some patients ... cause potentially fatal complications following transplantation. , "It,s ... medical director of Loyola University Medical Center,s LAM ...
(Date:4/17/2014)... 17, 2014-- Colic affects about one in five infants ... pediatric visits during the first several months after birth. ... was showing promise; however, the April 1, 2014 issue ... Valerie) reported on a study, "Probiotics and Infant Colic," ... reuteri for infant colic did not reduce ...
(Date:4/17/2014)... EcoHealth Alliance, a nonprofit organization that focuses on ... review today examining the current state of knowledge of ... for improved global surveillance strategies to combat the emergence ... Ebola in West Africa that has claimed the lives ... Liberia. According to the World Health Organization (WHO), ...
(Date:4/17/2014)... international research team led by Cesar A. Arias, M.D., ... at Houston (UTHealth) has identified a new superbug that ... report appeared in the April 17 issue of ... new superbug is part of a class of highly-resistant ... MRSA, which is a major cause of hospital and ...
Breaking Medicine News(10 mins):Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:New MRSA superbug emerges in Brazil 2
... , AVENTURA, Fla., Dec. 21 Cinergy ... benefit programs for the consumer market, expressed its concern for the ... this morning. , "While the Senate and House healthcare bills are ... step towards expanding access to affordable health coverage for all Americans," ...
... on edibles that will signal fullness just by chewing ... possible to create foods with hunger-suppressing aromas that would offer ... scientists say. , Researchers have long attempted to develop foods ... until recently, have focused on the effects of food in ...
... powerful results in mice and people, researchers say , ... a protein that may be involved in the development ... to new drugs to fight this growing worldwide scourge. ... inhibiting this pathway worked to block pain associated with ...
... ... schedules have been finalized for the ,second annual Dr. Alec Kessler Memorial High School ... Center., , ... (Vocus) December 21, 2009 -- The teams and the tournament schedules have been finalized for ...
... , BOCA RATON, Fla., Dec. 21 Flipping ... system for children and adults, has teamed up with Fisher ... to the retail value of $10,000 - to the children ... In an effort to make the holidays a bit ...
... , , AARP PENNSYLVANIA KEY VOTE NEWS ALERT , ATTENTION ... on key issues throughout the 111th Congress, and informing its nearly ... these key votes. , HARRISBURG, Pa., Dec. 21 The U.S. ... that will begin to bring needed relief to millions of Americans ...
Cached Medicine News:Health News:Cinergy Health Commentary on Senate Healthcare Vote 2Health News:Diabetes Insight Could Lead to Better Treatments 2Health News:Teams And Tournament Schedule Finalized For The Dr. Alec Kessler Memorial High School Basketball Invitational December 28-30, 2009 2Health News:Teams And Tournament Schedule Finalized For The Dr. Alec Kessler Memorial High School Basketball Invitational December 28-30, 2009 3Health News:Flipping for Phonics(TM) Helps Spread Cheer To Military Families In Fisher Houses(R) This Holiday Season 2Health News:Flipping for Phonics(TM) Helps Spread Cheer To Military Families In Fisher Houses(R) This Holiday Season 3Health News:AARP Applauds Senate for Moving Health Care Reform Forward 2Health News:AARP Applauds Senate for Moving Health Care Reform Forward 3
(Date:1/15/2014)... Jan. 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin ... provisional patent application concerning composition of matter, biological targets, ... tumor cell death.  This patent application ... stranded RNA molecules (VSRNAs) which interfere with the basic ...
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium Research ... market intelligence, the United States ... device markets will expand moderately through 2022, with ... In particular, increasing interest in drug-eluting beads (DEBs) ...
(Date:1/15/2014)... LAVAL, Quebec , Jan. 15, 2014  Valeant Pharmaceuticals ... VRX) announced that the applicable waiting period under the ... to the previously announced tender offer by its indirect ... the outstanding shares of common stock of Solta Medical, ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... Presented Along With Updated Phase 1 Colorectal Cancer ... Data at ... CHICAGO, June 1 /PRNewswire-FirstCall/,-- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ... results,from its ongoing randomized Phase 2 clinical trial in patients ...
... Greater Than 50% Response Rate and 100% Disease Control Rate Observed ... Patients with Medullary Thyroid Cancer, ... encouraging new data from an ongoing phase 1 clinical trial of,XL184, ... with advanced malignancies. The maximum tolerated dose (MTD) for,XL184 has been ...
Cached Medicine Technology:Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer 2Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer 3Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer 4Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer 5Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 2Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 3Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 4Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 5Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 6
The UniCel DxI 800 with its exceptional throughput, proven chemiluminescent technology, assay protocols like Access, Access 2, Synchron LXi 725 and load "on-the-fly" capability simplifies and automat...
... The Access immunoassay system ... access benchtop analyzer that ... assays, with panels that ... thyroid, infectious disease, blood ...
...
...
Medicine Products: